Regeneron Pharmaceuticals (REGN) |
|
544.1 -4.1 (-0.75%)
|
01-27 03:02 |
|
Open: |
558.91 |
Pre. Close: |
548.2 |
|
High:
|
556.95 |
Low:
|
542.14 |
|
Volume:
|
901,677 |
Market Cap:
|
58,059M |
|
|
|
|
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and BioNTech. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
559.564 - 562.512 |
562.512 - 565.019 |
|
Low:
|
535.201 - 538.52 |
538.52 - 541.343 |
|
Close:
|
538.675 - 544.282 |
544.282 - 549.051 |
|
Technical analysis |
as of: 2021-01-26 4:48:14 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 652.81  One year: 762.48 |
| Support: |
Support1: 502.11 Support2: 467.00 |
| Resistance: |
Resistance1: 558.91 Resistance2: 652.81 |
| Pivot: |
515.44 |
| Moving Average: |
MA(5): 541.57 MA(20): 507.15
MA(100): 541.20  MA(250): 543.56 |
| MACD: |
MACD(12,26): 11.44 Signal(9): 5.40 |
| Stochastic oscillator: |
%K(14,3): 88.31 %D(3): 90.05 |
| RSI: |
RSI(14): 67.01 |
| 52-week: |
High: 664.64 Low: 328.13 Change(%): 60.4 |
| Average Vol(K): |
3-Month: 94558 10-Days: 92831 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.REGN has closed below upper band by 20.2%. Bollinger Bands are 62% wider than normal. The large width of the bands suggest high volatility as compared to REGN's normal range. The bands have been in this wide range for 4 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Tue, 26 Jan 2021
Regeneron says its COVID-19 antibody cocktail can prevent infections, based on late-stage study - MarketWatch
Tue, 26 Jan 2021
Regeneron (REGN) Covid-19 Cocktail Shows Promise as 'Passive Vaccine' in Trial - Bloomberg
Mon, 25 Jan 2021
Regeneron Pharmaceuticals Inc. (REGN) Rises 1.94% for January 25 - Equities.com
Mon, 25 Jan 2021
Why Now Could Be a Good Time to Buy Regeneron Stock - Barron's
Wed, 20 Jan 2021
Investing in Regeneron Pharmaceuticals (NASDAQ: REGN) Stocks - Securities.io
Tue, 19 Jan 2021
Regeneron Pharmaceuticals Inc. (REGN) Rises 3.08% for January 19 - Equities.com
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Outperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
105 |
| Shares Float (M) |
101 |
|
% Held by Insiders
|
2.90 |
|
% Held by Institutions
|
92.17 |
|
Shares Short (K)
|
1,960 |
|
Shares Short P. Month (K)
|
2,010 |
Stock Financials |
|
EPS
|
27.290 |
|
EPS Est This Year
|
14.940 |
|
EPS Est Next Year
|
16.370 |
|
Book Value (p.s.)
|
96.010 |
|
Profit Margin
|
34.14 |
|
Operating Margin
|
33.76 |
|
Return on Assets (ttm)
|
13.0 |
|
Return on Equity (ttm)
|
30.6 |
|
Qtrly Rev. Growth
|
31.6 |
|
Gross Profit (p.s.)
|
38.528 |
|
Sales Per Share
|
88.117 |
|
EBITDA (p.s.)
|
31.947 |
|
Qtrly Earnings Growth
|
25.80 |
|
Operating Cash Flow (M)
|
2,170 |
|
Levered Free Cash Flow (M)
|
734 |
Stock Valuations |
|
PE Ratio
|
19.94 |
|
PEG Ratio
|
0.94 |
|
Price to Book value
|
5.67 |
|
Price to Sales
|
6.17 |
|
Price to Cash Flow
|
26.29 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
